| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| Other Sizes |
|
| Targets |
GGTase I (IC50 = 9.5 nM); FTase (IC50 = 53 μM)
|
|---|---|
| ln Vitro |
GGTI-2418 inhibits GGTase I and FTase activities with IC50s of 9.5±2.0 nM and 53±11 μM, respectively, a 5,600-fold selectivity toward inhibition of GGTase I versus FTase. With a Ki of 4.4±1.6 nM, GGTI-2418 exhibits competitive inhibition of GGTase I against the H-Ras-CVLL protein[1]. Treatment with GGTi-2418 (10–15 μM; 16 hours) delocalizes FBXL2 and stabilizes IP3R3[2].
|
| ln Vivo |
GGTI-2418 (100 mg/kg daily or 200 mg/kg every third day; 15 days) significantly slows the growth of breast tumor xenografts in nude mice with MDA-MB-231 xenografts[1].
In ErbB2 transgenic mice, GGTI-2418 (100 mg/kg daily; 5 days) causes the regression of mammary tumors that are driven by ErbB2[1]. The phosphorylation of Akt at S473 is significantly reduced as a result of GGTI-2418's inhibition of Rap1's geranylgeranylation. In vivo, p27 levels are also increased by GGTI-2418[1]. |
| Animal Protocol |
Nude mice implanted with MDA-MB-231 breast cancer tumors[1]
100 mg/kg daily or 200 mg/kg every third day Injected intraperitoneally; 15 days |
| References |
|
| Molecular Formula |
C23H31N5O4
|
|---|---|
| Molecular Weight |
441.52
|
| Exact Mass |
441.238
|
| Elemental Analysis |
C, 62.57; H, 7.08; N, 15.86; O, 14.49
|
| CAS # |
501010-06-6
|
| Related CAS # |
501010-05-5;501010-06-6 (free acid);1044590-78-4 (sodium);
|
| PubChem CID |
11539477
|
| Appearance |
Solid powder
|
| LogP |
2.262
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
32
|
| Complexity |
667
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
O=C1[C@]([H])(C([H])([H])C2C([H])=C([H])C([H])=C([H])C=2[H])N(C(N([H])[C@]([H])(C(=O)O[H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])[H])=O)C([H])([H])C([H])([H])N1C([H])([H])C1=C(C([H])([H])[H])N([H])C([H])=N1
|
| InChi Key |
COLCNDRDBCLVOC-ICSRJNTNSA-N
|
| InChi Code |
InChI=1S/C23H31N5O4/c1-15(2)11-18(22(30)31)26-23(32)28-10-9-27(13-19-16(3)24-14-25-19)21(29)20(28)12-17-7-5-4-6-8-17/h4-8,14-15,18,20H,9-13H2,1-3H3,(H,24,25)(H,26,32)
|
| Chemical Name |
(2S)-2-[[(2S)-2-benzyl-4-[(5-methyl-1H-imidazol-4-yl)methyl]-3-oxopiperazine-1-carbonyl]amino]-4-methylpentanoic acid
|
| Synonyms |
GGTI2418; GGTI 2418; GGTI-2418; PTX 100; PTX-100; PTX100
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~125 mg/mL (~283.1 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.71 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.71 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.71 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2649 mL | 11.3245 mL | 22.6490 mL | |
| 5 mM | 0.4530 mL | 2.2649 mL | 4.5298 mL | |
| 10 mM | 0.2265 mL | 1.1325 mL | 2.2649 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT03900442 | Unknown | Drug: PTX-100 | Advanced Cancer PTCL |
Prescient Therapeutics, Ltd. | September 1, 2019 | Phase 1 |
|
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
